Degrader-antibody conjugates-Reference-Cited by-同舟云学术

Degrader-antibody conjugates

Published:2022 Issue:10 Volume:51 Page:3886-3897
ISSN:0306-0012
Container-title:Chemical Society Reviews
language:en
Short-container-title:Chem. Soc. Rev.

Author:

Dragovich Peter S.¹^ORCID

Affiliation:

1. Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Abstract

This review illustrates the design of antibody conjugates which employ chimeric protein degraders (i.e., PROTACs) as payloads and summarizes the examples of such entities that are currently known in the scientific and patent literature.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/CS/D2CS00141A

Reference45 articles.

1. PROTAC targeted protein degraders: the past is prologue

2. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges

3. Fundamental aspects of DMPK optimization of targeted protein degraders

4. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective

5. Developing degraders: principles and perspectives on design and chemical space

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads;European Journal of Medicinal Chemistry;2024-10

2. Liver-targeting chimeras as a potential modality for the treatment of liver diseases;Journal of Controlled Release;2024-10

3. The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges;Journal of Medicinal Chemistry;2024-09-04

4. Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy;Chemical Engineering Journal;2024-09

5. New techniques and strategies in drug discovery (2020–2024 update);Chinese Chemical Letters;2024-09